idiopathic pulmonary fibrosis

News

Redx shares soar after IPF drug licence deal with AstraZenec...

Shares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to AstraZeneca.

News

Roche increases IPF presence with $1.39bn Promedior buy

Roche has agreed to buy US biotech Promedior, and a portfolio of drugs including a promising molecule for the deadly lung-scarring disease idiopathic pulmonary fibrosis (IPF) in a deal wort

News

AZ researches kidney and lung drugs with BenevolentAI

AstraZeneca has become the latest big pharma to jump on the artificial intelligence R&D bandwagon, penning a deal with the UK’s BenevolentAI to find new kidney and lung drugs.<

News